Stock price when the opinion was issued
Shares are down because the market fears they will do a tie-up deal with Humana, but CI bowed out. This is good given Human's problems. Managers are excellent, making good deals. EPS grew 13% compounded annual growth rate from 2013-2023. Are buying back shares and pay a dividend.
(Analysts’ price target is $397.05)
Exited, and allocated proceeds to UNH, as it's a better performer, larger scale. He also had concerns over customer concentration. Not expensive at 12x forward earnings plus 1.7% yield.